Related Experiment Video

Updated: Dec 22, 2025

Optimized Analysis of In Vivo and In Vitro Hepatic Steatosis
08:58

Optimized Analysis of In Vivo and In Vitro Hepatic Steatosis

Published on: March 11, 2017

16.7K

Can cysteinyl cathepsin activity control diet-induced NAFLD?

Chenglin Yu1, Ying Wan1, Limei Piao1

  • 1Department of Cardiology and Hypertension, Yanbian University Hospital, Yanji, China.

International Journal of Cardiology. Heart & Vasculature
|May 7, 2020
PubMed
Summary

No abstract available in PubMed .

Keywords:
CSTB, cathepsin BCTSB+/+, wild-typeCTSB−/−, cathepsin B deficiencyCTSs, cathepsinsFABP4, fatty acid binding protein 4FPC, fructose-palmitate-cholesterolLDL, low density lipoproteinMMP, metalloproteinaseNAFLD, Non-alcoholic fatty liver diseaseNASH, non-alcoholic steatohepatitisScad, short-chain acyl dehydrogenase-1

More Related Videos

Investigating the Protective Effects of Platycodin D on Non-Alcoholic Fatty Liver Disease in a Palmitic Acid-Induced In Vitro Model08:20

Investigating the Protective Effects of Platycodin D on Non-Alcoholic Fatty Liver Disease in a Palmitic Acid-Induced In Vitro Model

Published on: December 2, 2022

2.1K
Incorporation of a Survivable Liver Biopsy Procedure in Mice to Assess Non-alcoholic Steatohepatitis NASH Resolution04:14

Incorporation of a Survivable Liver Biopsy Procedure in Mice to Assess Non-alcoholic Steatohepatitis NASH Resolution

Published on: April 16, 2019

12.5K

Related Concept Videos

Atherosclerosis III: Management01:26

Atherosclerosis III: Management

Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...
263
Nephrotic Syndrome II : Assessment and Medical Management01:26

Nephrotic Syndrome II : Assessment and Medical Management

IntroductionNephrotic syndrome is a kidney disorder marked by excessive protein loss in the urine, leading to various systemic complications. This condition often results from damage to the glomeruli—the kidney's filtering units—causing proteinuria, low blood protein levels, and fluid retention. Understanding the assessment, diagnosis, and management of nephrotic syndrome is essential for effective treatment and prevention of further kidney damage.AssessmentPatient History: Document...
145